Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.78 |
| ▸ | ESR1 | P03372 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.78 |
| ▸ | AKT1 | P31749 | 2/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.62 |
| ▸ | APP | P05067 | 3/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808504 | 0.88 | PDE4D (1.00) | PDE5AESR1PDE4DESR2AKT1 | |
| SCHEMBL1231403 | 0.88 | PDE4D (1.00) | PDE5AESR1PDE4DESR2AKT1 | |
| SCHEMBL20045159 | 0.84 | DYRK1A (0.84) | PDE5AESR1PDE4DESR2AKT1 | |
| SCHEMBL4227433 | 0.84 | PDE5A (0.80) | PDE5AESR1PDE4DESR2AKT1 | |
| SCHEMBL26114536 | 0.83 | KDM4E (0.55) | PDE5AESR1PDE4DESR2AKT1 | |
| Sophoflavescenol SCHEMBL29612027 | 0.82 | PDE5A (0.73) | PDE5AESR1PDE4DESR2KDM4E | |
| Sophoflavescenol SCHEMBL14563970 | 0.82 | PDE5A (0.73) | PDE5AESR1PDE4DESR2KDM4E | |
| SCHEMBL28950297 | 0.82 | SLC22A2 (0.72) | PDE5AESR1PDE4DESR2AKT1 | |
| SCHEMBL3192297 | 0.82 | AKT1 (0.71) | PDE5AESR1PDE4DESR2AKT1 | |
| SCHEMBL20045166 | 0.82 | DYRK1A (0.71) | PDE5AESR1PDE4DESR2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221944-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | KBLUEBIO INC (KR) | 2025-07-10 | — | — | US | disclosed |
| EP-4506328-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | KBlueBio Inc (KR) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023195791-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | 케이블루바이오 주식회사 | 2023-10-12 | — | — | WO | disclosed |
| US-9527860-B2 | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders | Aigner, Ludwig (AT) | 2016-12-27 | — | — | US | disclosed |
| US-9527860-B2 | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders | Aigner, Ludwig (AT) | 2016-12-27 | — | — | US | disclosed |
| US-20140349919-A1 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS | COUILLARD-DESPRES, Sébastien (AT) | 2014-11-27 | — | — | US | disclosed |
| US-20140349919-A1 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS | COUILLARD-DESPRES, Sébastien (AT) | 2014-11-27 | — | — | US | disclosed |
| US-20110130447-A1 | Production of hop extracts having oestrogenic and antiproliferative bioactivity | MAES FRANCIS | 2011-06-02 | — | — | US | disclosed |
| US-7326734-B2 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-05 | — | — | US | disclosed |
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | KLK5, KLK4, KLK6 | PDE5A 2937/4885ESR1 790/4885PDE4D 3447/4885 |
| US-20140349919-A1 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS | BDNF, MAP2, DCX | PDE5A 1931/4885ESR1 3797/4885PDE4D 846/4885 |
| US-20250221944-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | MCL1, CRBN, BCL3 | PDE5A 1889/4885ESR1 3399/4885PDE4D 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.